J Am Dent Assoc. 2020 Apr;151(4):245-254.e24. doi: 10.1016/j.adaj.2019.10.010. Epub 2020 Jan 23.
This objective of this umbrella review was to summarize the evidence on safety, efficacy, and effectiveness of human papillomavirus (HPV) vaccines in the general population.
The authors conducted a literature search and selected systematic reviews if they were published from January 2006 through November 2018, included randomized controlled trials or observational studies, related to the general population, and evaluated HPV vaccine-related clinical outcomes. The authors independently and in duplicate screened literature, extracted data, and appraised reviews using AMSTAR 2, a critical appraisal tool for systematic reviews.
The authors selected 30 systematic reviews that included male and female participants aged 9 through 76 years from multiple countries. Reviews evaluated postvaccine seroconversion, HPV infection rates, precancerous or benign lesions, and adverse events; none of the researchers reported on oral or oropharyngeal lesions. Results from the reviews showed that, compared with those who received a placebo or non-HPV-type vaccine, HPV-vaccinated participants had statistically significantly higher rates of seroconversion and local adverse events, statistically significantly lower rates of HPV infection and condylomata lesions, and decreased rates of HPV-related precancerous lesions, which did not always attain statistical significance.
Systematic reviews have found evidence that the available HPV vaccines are safe, effective, and efficacious against vaccine-type HPV infection and HPV-associated cellular changes, including precancerous and benign lesions.
Dentists may use this resource to better understand the literature on the potential harms and benefits of HPV vaccination.
本综述的目的是总结普通人群中 HPV 疫苗的安全性、有效性和效果的证据。
作者进行了文献检索,如果系统评价发表于 2006 年 1 月至 2018 年 11 月,纳入随机对照试验或观察性研究,与普通人群相关,并评估 HPV 疫苗相关的临床结局,则将其纳入。作者独立且重复筛选文献、提取数据,并使用 AMSTAR 2 对系统评价进行评估,这是一种系统评价的关键评估工具。
作者选择了 30 篇系统评价,这些评价纳入了来自多个国家的 9 至 76 岁的男性和女性参与者。评价结果评估了疫苗接种后的血清转化率、HPV 感染率、癌前病变或良性病变以及不良事件;但没有研究人员报告口腔或口咽病变。这些综述的结果表明,与接受安慰剂或非 HPV 型疫苗的参与者相比,HPV 疫苗接种者的血清转化率和局部不良事件发生率更高,HPV 感染和湿疣病变率更低,HPV 相关癌前病变率也更低,但这些结果并不总是具有统计学意义。
系统评价发现证据表明,现有的 HPV 疫苗在预防 HPV 型感染和 HPV 相关细胞变化方面是安全、有效和有效的,包括癌前病变和良性病变。
牙医可以使用此资源来更好地了解 HPV 疫苗接种的潜在危害和益处的文献。